ID   LN229/CD19
AC   CVCL_D2TH
RX   PubMed=32271687;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 1633; CD19 (with a C-terminal DMVNPGLEDRIE = RAP-tag and GDGMVPPGIEDK = MAP-tag).
CC   Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0393 ! LN-229
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   PubMed=32271687; DOI=10.1089/mab.2020.0003;
RA   Yamada S., Kaneko M.K., Sayama Y., Asano T., Sano M., Yanaka M.,
RA   Nakamura T., Okamoto S., Handa S., Komatsu Y., Nakamura Y.,
RA   Furusawa Y., Takei J., Kato Y.;
RT   "Development of novel mouse monoclonal antibodies against human
RT   CD19.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 39:45-50(2020).
//